[1]高秋英, 荀利如, 李岚, 等. 上调miR-125a-5p抑制急性髓系白血病细胞系的增殖和侵袭[J]. 基础医学与临床, 2021, 41: 1594-1605. [2]Appelbaum Fr,Gundacker H,Head Dr,et al. Age and acute myeloid leukemia [J]. Blood,2006,107:3481-3485. [3]Juliusson G,Antunovic P,Derolf A,et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry [J]. Blood,2009,113:4179-4187. [4]Keiffer G, Palmisiano N. Acute myeloid leukemia: update on upfront therapy in elderly patients [J]. Curr Oncol Rep,2019,21:71.doi:10.1007/S11912-019-0823-1. [5]Ossenkoppele G and Löwenberg B. How I treat the older patient with acute myeloid leukemia [J]. Blood,2015,125:767-774. [6]Gupta S,Yel L,Kim D,et al. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2 [J]. Mol Cancer Ther,2003,2:711-719. [7]Joe Y,Jeong Jh,Yang S,et al. ATR,PML,and CHK2 play a role in arsenic trioxide-induced apoptosis [J]. J Biol Chem,2006,281:28764-28771. [8]Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy [J]. Oncogene,2002,21:5483-5495. [9]Cashen Af,Schiller Gj,O'donnell Mr,et al. Multicenter,phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia [J]. J Clin Oncol,2010,28:556-561. [10]刘应彬,朱熙君. 地西他滨联合三氧化二砷方案治疗老年中高危骨髓增生异常综合征的应用价值 [J]. 安徽医学,2020,41:943-946. [11]张彦平,刘蒙蒙,展新荣. 地西他滨联合三氧化二砷治疗老年急性髓系白血病的疗效及安全性 [J]. 新乡医学院学报,2019,36:1163-1166. [12]陈思思,赵彦平,吴文忠,等. 地西他滨联合三氧化二砷对急性髓系白血病MV4-11细胞增殖和凋亡的影响 [J]. 中国实验血液学杂志,2016,24:1343-1347. [13]Tamburini J,Elie C,Bardet V,et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients [J]. Blood,2007, 110:1025-1028. |